PDS BIOTECHNOLOGY CORPORATION - COMMON STOCK

PDS Biotech Announces Expansion of its VERSATILE-002 Clinical Trial into Europe

31 May 2022 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer at ASCO 2022

26 May 2022 16:02:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Presentation of Data from NCI-Led Triple Combination Phase 2 Clinical Trial in Advanced, Refractory HPV-Positive Cancers at ASCO 2022

26 May 2022 16:01:00 By Nasdaq GlobeNewswire

PDS Biotechnology to Host Conference Call Following Poster Presentations of PDS0101 Data at 2022 ASCO Annual Meeting

25 May 2022 07:00:01 By Nasdaq GlobeNewswire

PDS Biotechnology Appoints Seasoned Business Development Executive Sanjay Zaveri as Senior Vice President, Business Development

18 May 2022 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech to Participate at Upcoming Investor Conferences

17 May 2022 07:00:04 By Nasdaq GlobeNewswire

PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial Results

11 May 2022 06:00:02 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2022 Financial Results

28 Apr 2022 07:00:02 By Nasdaq GlobeNewswire

PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

27 Apr 2022 09:01:00 By Nasdaq GlobeNewswire

PDS Biotech Chief Medical Officer, Lauren V. Wood, to Chair Session at the World Vaccine Congress

20 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Receives $1.2 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

19 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2021 Financial Results

31 Mar 2022 06:00:02 By Nasdaq GlobeNewswire

PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call

22 Mar 2022 18:30:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers

15 Mar 2022 06:45:00 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter and Full Year 2021 Financial Results

09 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

PDS Biotechnology to Present at the 32nd Oppenheimer Annual Healthcare Conference

01 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium

24 Feb 2022 09:10:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer

15 Feb 2022 07:00:04 By Nasdaq GlobeNewswire

PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer

02 Feb 2022 07:00:01 By Nasdaq GlobeNewswire